The Safety of Etomidate - Propofol Mixture vs Propofol in Total Intravenous Anesthesia During Abdominal Surgery

• Status: Not yet recruiting
• Trial end date: 2024-08-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to access the safety of etomidate - propofol mixture vs propofol in total intravenous anesthesia during abdominal surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ailin Luo
• Treatments: Etomidate; Propofol

Criteria

Inclusion Criteria:

• ASA Ⅰ~Ⅲ;

• BMI was 18-28 kg/m2;

• For elective abdominal surgery under intravenous general anesthesia;

• The expected duration of anesthesia was 1 to 4 hours.

Exclusion Criteria:

• Pregnant patients;

• Septic shock and multiple organ failure diagnosed within 14 days;

• Hyperkalemia (serum potassium >5.5mmol/L) within 48 hours;

• Stroke or transient ischemic attack within 3 months;

• Patients with unstable angina pectoris or myocardial infarction within 3 months; Arrhythmia requiring treatment was not treated or treatment did not meet expectations;

• Patients with preoperative diagnosed diabetes mellitus and uncontrolled blood glucose; Diabetic complications were diagnosed before surgery, including diabetic ketoacidosis, hyperosmolar coma, diabetes-related infection, diabetic nephropathy, retinopathy, diabetic cardiomyopathy, diabetic neuropathy, diabetic foot, etc.

• Severe liver and renal dysfunction;

• Liver surgery, renal surgery, adrenal surgery, day surgery;

• Resting blood pressure ≥180/110 mmHg (2020 ISH hypertension guideline ≥ grade 3 hypertension); Or systolic blood pressure <90mmHg or mean blood pressure <65mmHg.

• Taking corticosteroids or other immunosuppressants for more than 10 days within 6 months or having a history of adrenal cortex suppression or immune system diseases;

• Patients who participated in other drug trials within 3 months;

• Patients with disturbance of consciousness or other mental diseases;

• Confirmed/suspected abuse or long-term use of narcotic sedatives and analgesics；

• Patients with cancer who received neoadjuvant therapy or chemotherapy before surgery;

• Allergic to the drug used in this trial and its components.